Temasek Holdings to Increase Investment in Celltrion
Singapore’s Temasek Holdings plans to invest US$ 129 million in Celltrion Inc., a Korean biotechnology company. Temasek Holdings is the number two shareholder in Celltrion at a 10.5% stake. The Singapore sovereign fund is also the third largest shareholder in Celltrion Healthcare Co. at a 7.7% stake. Founder, Seo Jung-jin plans to sell his stakes in both companies in the Celltrion Group. Temasek Holdings purchased 1 million shares of Celltrion in after-hours trade and plans to buy more this week.
Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute